Centre Hospitalier Departemental Vendee

chd-vendee.fr

Total trials

82

Active

16

Phase 3

7

Total enrollment

30,646

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 4 of 4 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Corticosteroid2
Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®1
Hyaluronic acid1
Systemic Analgesia Only Group1

Next readouts

  • 2026-01-14
  • 2026-05-31
  • 2026-12-19
  • 2028-03

Top conditions

  • Cardiac Arrest4
  • Acute Respiratory Failure3
  • Shock3
  • Pregnancy3
  • Ventilator-associated Pneumonia3
  • Breast Cancer2
  • Kidney Failure, Chronic2
  • Hypothermia2

Frequently asked questions about Centre Hospitalier Departemental Vendee

How many clinical trials does Centre Hospitalier Departemental Vendee have on ClinicalTrials.gov?
Centre Hospitalier Departemental Vendee is listed as the lead sponsor on 82 clinical trials in ClinicalTrials.gov, 16 of which are currently active (recruiting, enrolling, or ongoing).
How many of Centre Hospitalier Departemental Vendee's trials are in Phase 3?
7 of Centre Hospitalier Departemental Vendee's trials are in Phase 3, spread across 4 active drug programs.
What therapeutic areas does Centre Hospitalier Departemental Vendee focus on?
Centre Hospitalier Departemental Vendee's most-studied conditions on ClinicalTrials.gov are Cardiac Arrest, Acute Respiratory Failure, Shock, Pregnancy, Ventilator-associated Pneumonia.
When are Centre Hospitalier Departemental Vendee's next clinical trial readouts?
Centre Hospitalier Departemental Vendee has 4 upcoming primary-completion readouts tracked here; the soonest is “Impact of Loco-regional Analgesia Following Placement of Erector Spinae Plane Catheter in Addition to Systemic Analgesia in Patients With Thoracic Trauma”, expected around 2026-01-14.